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Abstract
Genomic-based information is an essential key to precise therapy referred to 
as personalized medicine. Its application in autoimmune disease treatment will 
bring the required breakthrough in medicine. Autoimmune diseases are the disease 
conditions where the body’s immune system recognizes and generate an immune 
response against self-antigens. There exist different approaches of which precision 
medicine data can be utilized in the clinical management of autoimmune diseases; 
this includes diagnosis, prognosis, stratification and treatment response prediction. 
Different markers exist to guide clinical decision while several others are still being 
identified and proposed. This chapter highlights data and databases in precision 
medicine of autoimmune diseases and the pathway for data sharing. The precision 
medicine of selected autoimmune diseases was discussed, and the different bio-
markers utilized in the diagnosis, prognosis, stratification and response monitoring 
of such condition were considered.
Keywords: autoimmune diseases, databases, genomic data, personalized medicine, 
precision medicine
1. Introduction
The functional responsibility of the immune system (humoral and cell-mediated 
alike) is to protect against infection by destroying various infectious agents when 
such agents attack the body or are introduced through vaccination [1]. The func-
tioning of the immune system is coordinated and maintained by a sequence of 
highly regulated and physiological mechanisms which aids the identification and 
recognition of both body cells and foreign cells [2].
The body’s immune units usually coexist with other cells of the body that carries 
a self-marker molecule. Immune reactions are only triggered when an antigen which 
could be a microbe, part of a microbe or a molecule is presented to the surface of the 
cell and perceived by the body defenses [3].
The immune system of humans is made up of two divisions which are innate and 
acquired immunity. The innate immunity forms the first line of defense immedi-
ately after infectious agents are recognized by the body while acquired immunity 
functions in the removal of pathogens at the later phase of infection [3].
When the immune system is stimulated, it targets and destroys foreign units. 
Still, in some abnormal situation, the immune system might be insensitive to anti-
gens, hypersensitive to antigens or recognize the cells with self-marker as foreign 
cells [2].
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There are disease conditions that affect the immune system, which leads to 
different degree and types of conditions known as the Immune diseases. Diseases 
of the immune system include inherited and acquired immunodeficiency and 
immune-proliferative disorders which includes malignancies of the immune system 
(multiple myeloma, lymphoma, and leukemia), autoimmune diseases (rheumatoid 
arthritis), and immune hypersensitivities (allergies) [4]. Inherited immunodefi-
ciency, also is known as primary immunodeficiency, refers to a large number of 
immune disorders which alters either or both development and function of the 
immune system. Primary immunodeficiency implies conditions resulting from loss 
of function, a gain of function or loss of expression due to monogenic germline 
mutations [5]. External and environmental factors can induce an adverse effect on 
the immune system, and this is regarded as secondary or acquired immunodefi-
ciency, which is encountered commonly in clinical practice and could arise from 
quite a number of conditions [6].
The evolvement of medical practices especially diagnosis and treatment from 
the usual “one size fits all” approach to a more genetic and detailed patient strati-
fication in a bit to acquire more information about the disease condition and the 
patient is known as personalized medicine [7].
The complexity of the body defense system and the ability of the cells associated 
with it to shift between different activation states under physiological and patho-
logical conditions are some of the reasons for diversity in the treatment approach. 
The immune diseases at times are diverse, and this result in variations in response 
to therapy. The difference in the disease course also create reasons why there should 
be the identification of personalized marker for diagnosis of immune disease. 
Therefore, the use of genetic assessment to determine the best possible therapeutic 
approach from the numerous available options with different mechanisms, risks, 
and efficacy are essential [7, 8].
The Precision medicine data types, genomic data in precision medicine, genomic 
and personalized medicine databases, data sharing, access and use are discussed 
in this chapter. Also, the use of genomic methods and data in the understanding, 
diagnosis of diseases using specific biomarkers, monitoring of prognosis using 
prognosis biomarkers, personalized treatment of immune disorders, monitoring of 
response to treatment using response biomarkers are also described in this chapter.
2. Precision medicine of specific autoimmune diseases
2.1 What is immunity?
Immunity is the ability of the body to prevent infection by resisting the invasion 
of such a body by harmful microorganism knows as infectious agents. Immunity 
can be categorized broadly into two types which are:
i. Innate or Natural Immunity and
ii. Acquired Immunity
2.1.1 Innate or natural immunity
The initial host protection against diseases- causing agents is the innate 
immunity which is mediated by phagocytes. Through germline-encoded pattern-
recognition receptors (PRRs), the innate immunity of the human body recognizes 
3
Precision Medicine of Autoimmune Diseases
DOI: http://dx.doi.org/10.5772/intechopen.95248
microorganisms invading its body. For the immune cells to be activated, different 
classes of the PRRs, which include Toll-like receptors and cytoplasm receptors 
recognize distinct and important microbial component of invading microorganisms 
thereby activating immune cells [3, 9].
2.1.1.1 Mechanism of action of innate or natural immunity
Immediately after the detection of non-self-agents by PRRs which could be 
exhibited on the outer membrane of the cell, in intracellular parts, or released in the 
bloodstream and fluids of the body tissues, the PRRs then perform the function of 
opsonization, stimulation of complement and coagulation outflow, phagocytosis, 
initiation of pro-inflammatory signaling pathways, and inception of apoptosis. 
These cascades of intracellular signaling induce the expression of overlapping 
and unique genes which are involved in the inflammatory immune responses and 
essential in precision medicine. The reaction by the innate immune system is car-
ried out by phagocytes (neutrophils, monocytes, and macrophages), inflammatory 
mediators releasing cells (basophils, mast cells, and eosinophils), and natural killer 
(NK) cells [3, 10].
2.1.2 Acquired immunity
Acquired immunity is the immunity that is developed against an infectious agent 
by the body after the previous encounter with a pathogen or a type of immunity 
developed by a child by the exchange of protective materials from mother to child 
before and after birth or by the injection of such substances. The mediation of 
adaptive immunity is the function of clonally distributed T and B Lymphocytes 
whose characteristics are the possession of specificity and memory. Many at times, 
activation of the innate immune response can trigger acquired immunity. The gen-
eration of Helper T cells subsets and the production of cytokines influence adaptive 
immunity [11, 12].
2.1.2.1 Mechanism of action of acquired immunity
When naïve T-helpers cells are stimulated by Antigen-presenting Cells otherwise 
known as APCs, they differentiate into two subsets of T helper (TH) cells such as 
TH1 and TH2. Interferon-γ (IFN-γ) is produced by TH1 cells that solely promote 
cellular immunity. TH2 cells, on the other hand, produce interleukin 4, 5, 10 and 
13 (IL-4, IL-5, IL-10, and IL-13). Whereas, IL-12 is the propelling source of TH1 
separation while IL-4 stimulates TH2 distinction. TH2 is majorly involved in the 
promotion of humoral immunity [12].
2.1.3 Pathogenesis of immune diseases
The occurrence of the immunological disease is consequent to the dysregulation 
of numerous and different part of the human immune system. Fundamentally, the 
response of the immune system recognizes and eliminates antigens but tolerates 
its tissues. However, predominant immunopathology lesion is the basis on which 
the characterization of immune-mediated diseases is based. Immune-mediated 
disorders can be grouped into immediate hypersensitivity, autoimmunity, immune-
complex disease, and delayed-type hypersensitivity. Autoimmunity can be further 
classified into those mediated by adaptive immunity and those mediated by innate 
immunity. Most of the disorders lie between the two, which will be best described 
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as positive pathological feedback between innate and adaptive immune mechanisms 
[13]. Figure 1 below represents the pathogenesis of immune diseases.
2.2 Personalized medicine
Personalized medicine is the process of tailoring the diagnostic procedures, 
treatment, and preventive measures towards the characteristics of individual 
patients to get an optimal outcome for each patient while emphasizing easy acces-
sibility and cost-effectiveness [14]. In the practice of personalized medicine, the 
characteristics of an individual, including the uniqueness of its genetic profile 
guide the clinical decision in the treatment. Prognostic, diagnostic and predictive 
biomarkers are always being searched to guide these clinical decisions, at the same 
time, ensure that the best treatment is offered to the right patient at the best time 
[15]. The division of personalized medicine is illustrated in Figure 2.
While the method of application of precision medicine is given in Figure 3.
2.2.1 Personalized medicine and genomic data
Generally, personalized medicine compose of a vast collection of genetic data. 
The development of power systems has helped to increase the effective use of 
big data in personalized or precisions medicine over time. Also, the evolution of 
genomics data offers limitless possibilities in the design of clinical procedures, 
diagnostic, prevention, addressing and prediction of most favorable therapeutics 
for many diseases that are related to different regions and lineage [16].
Figure 1. 
Schematic representation of the pathogenesis of immune diseases.
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2.2.2 Precision medicine data types
The systematic collection of patient information is now accumulating and 
gaining complexity, as seen in the case of neuroimaging, which is currently produc-
ing above ten petabytes of data every year [17]. Studies in the field of precision 
medicine research make use of relevant data types such as Imaging data (CT, PET, 
UltraSound and MRI), bio-sample data (serum, plasma and urine value), molecu-
lar data, genomics data (nucleotide sequences), proteomic profiling data (mass 
Figure 2. 
Diagram showing the different division of precision medicine.
Figure 3. 
A flow chart representing application method of precision medicine.
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spectrometry), digital pathology data, biomedical instrument data (blood pressure, 
heart rate and insulin level) and clinical data (death/survival data, demographics 
and medical-based questionnaire) and others [18].
Some of the achievement in Precision medicine has led to solutions, such as 
the birth of personalized brain models for a patient with intractable epilepsy [19] 
and the success in epigenetics mechanism of hematopoiesis [20]. The combination 
and integration of these data types require a sound understanding of the differ-
ent fields of informatics (data science, data management and data curation) and 
bioinformatics [18].
2.3 Genomic and personalized medicine database
A database is an ordered set of structured information or data usually controlled 
by the database management system (DBMS) in an electronic computer. The data, 
DBMS and the applications associated with them are called database system or data-
base in short. Each database contains certain types of data; here, we will be intro-
ducing some of the database associated with personalized or precision medicine.
2.3.1 Immune epitope database (IEDB)
The IEDB is a free to use database that is very useful in vaccine and drug devel-
opment, this database catalogs data such as experimental data on antibodies, Major 
histocompatibility complex (MHC) binding data from different antigenic sources, 
Helper T lymphocyte (HTL) and Cytotoxic T Lymphocytes (CTL) epitopes for 
human and other animal species. This database also aids in prediction and analysis 
of varieties of epitopes [21]. This database can be accessed through https://www.
iedb.org/.
2.3.2 Prostate cancer related lifestyle database (PCaLiStDB)
Lifestyle medicine is the study of association between lifestyle, chronic and 
immune diseases. PCaLiStDB is a lifestyle database that is channeled towards preci-
sion in the prevention of prostate cancer and other diseases associated with lifestyle. 
The data found in this database are lifestyle associated genes, lifestyle type bio-
markers and personalized lifestyle-disease associated predictors [22]. The database 
link is http://www.sysbio.org.cn/pcalistdb/.
2.3.3 Clinical genome resources (ClinGen)
ClinGen database provides data that are of clinical importance, this database 
is funded by the National Institute of Health (NIH), and it is aimed at collecting 
necessary data for use in precision medicine and research. Data such as clinically 
relevant gene and variants are retrieved from this database in making precise diag-
nosis and treatment [23]. This database is accessed via https://clinicalgenome.org/.
2.3.4 Personal genome project (PGP)
One of the breakthroughs of medical informatics is the personal genome project 
database. This is an open-access database that is channeled towards the develop-
ment of a tool for personalized medicine and advancing research. The database 
provides a wide range of data for different regions (PGP-UK, PGP-AUSTRIA, PGP-
CHINA, PGP-CANADA and PGP-UNITED STATE, etc.). Data such as Genome, 
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Methylome, transcriptome and phenotype data are retrieved from this database for 
use in the procedure of precise medicine [24]. The database can be linked through 
https://www.personalgenomes.org/.
2.3.5 Online mendelian inheritance in man (OMIM)
This database was initiated in the early 1960s, and the online version was 
created in 1985. OMIM is an open-access database that is mainly built for profes-
sionals concerned with genetic disorders, a genetics researcher and advance stu-
dents in medicine. Data such as human gene, genetic disorders, clinical features, 
phenotype and genes are available [25, 26]. This database address is https://www.
omim.org/.
2.3.6 Human gene mutation database (HGMD)
This is a variant-related database that collates already known gene lesion that is 
responsible for human inherited diseases. The database includes precision medicine 
data such as gene symbol, genomics coordinates, splicing, different disease, phe-
notype and mutations in the human genome [27, 28]. This database is accessible via 
http://www.hgmd.cf.ac.uk/ac/index.php.
2.3.7 Clinical genome database (CGD)
Clinical Genomic Database fills the critical niche in the field of clinical and 
genomic medicine; it also encompasses medically significant genetic data with 
available interventions. For each entry in the database, the CGD gives out data such 
as allelic conditions, gene symbol, clinical categorization (both manifestation and 
interventions), affected age groups mode of inheritance and pathogenic muta-
tion for all diseases so far captured [27]. This database can be accessed via https://
research.nhgri.nih.gov/CGD/.
2.3.8 Other database related to precision/personalized medicine
There are other ongoing database projects to improve the existing ones, an 
example of this is The Human Variome Project [29]. Also, there are many websites 
and databases linked to precision medicine that this chapter cannot introduce 
all. Table 1 below provides more of the database related to precision medicine in 
general and their links [30].
2.4 Genomic and personalized medicine data utilization
Data sharing is the potential inherent in the exchange of the same data 
resource with many applications or users; it encompasses the transferring of 
copies, accessing and enabling the reuse of data. Data can be open access (publicly 
available) or controlled (restricted), also, sharing data encompasses both sharing 
of primary (in case of nucleotide sequences) and secondary data (already used or 
analyzed data) [31].
Figure 4 above illustrates that precision medicine data encompasses both 
hospital data (information), GIS and PGHD. Sharing of the Precision medicine 
information (clinical data) can be accessed openly or otherwise restricted, whereby 
authorization will be needed by an authorized person to access and use the specified 
data for therapeutic, diagnostic and research purpose.
Innate Immunity in Health and Disease
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2.5 Precision medicine of specific autoimmune diseases
Autoimmune diseases are disease conditions where the immune system respond 
to self-antigens as a result of damage or dysfunction or disorder in the tissues. It 
is controlled by a whole lot of factors of which host gene and environment play a 
vital role. It could affect the entire body, selected systems or selected organs and an 
Database Link
Pathway Interaction Database http://pid.nci.nih.gov/
VirusMINT (interaction between viral 
protein and human)
http://mint.bio.uniroma2.it/virusmint/Welcome.do
AutDB (animal model resources) http://autism.mindspec.org/autdb/AMHome.do
Pathogen Interaction Gateway
((host and pathogen interaction)
http://molvis.vbi.vt.edu/ or
http://pathogenportal.net/pig/
NetPath (signal transduction) http://www.netpath.org/
Entrez – (encompasses sub-Databases) http://www.ncbi.nlm.nih.gov/sites/gquery
GeneCards http://www.genecards.org/
Human Genome Resources http://www.ncbi.nlm.nih.gov/projects/genome/guide/human/
Ensembl Human Genome Browser http://www.ensembl.org/IIomo_sapiens/Info/





National Institute of Neurological 
Disorders and Stroke (NINDS): Clinical 
and Translational Resources
http://www.ninds.nih.gov/research/scientific_resources/clinical/
Database of Genotypes and Phenotypes 
(dbGaP)
http://www.ncbi.nlm.nih.gov/sites/entrez?db=gap
NIH Chemical Genomics Center http://www.ncgc.nih.gov/]
Gene Expression Omnibus http://www.ncbi.nlm.nih.gov/geo/





Human Genome Project, NHGRI http://www.genome.gov/10001772
NCBI BioSystems http://www.ncbi.nlm.nih.gov/biosystems/
National Human Genome Research 
Institute (NHGRI)
http://genome.gov
Kyoto Encyclopedia of Genes and 
Genomes
http://www.genome.jp/kegg/
HUPO Brain Proteome Project http://www.hbpp.org/5602.html
ExPASy Proteomics Server http://expasy.org/
HUPO: Human Proteome Organization http://www.hupo.org/




Database linked to precision medicine in general and their links [30].
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interplay between genetic makeup with environmental factors and the self-antigen 
presented for recognition controls which organ or system of the body that will 
become the target of the immune system [32, 33].








7. Type 1 Diabetes
2.5.1 Genomic assessment of multiple sclerosis
Multiple sclerosis is an inflammatory/autoimmune disorder that selects the 
myelin in the central nervous system which is capable of affecting patients of all age 
and causing neurologic disability when not adequately managed [34, 35]. More than 
Figure 4. 
Semantic diagram of genomic and personalized medicine data sharing (LIS: Laboratory Information System; 
GIS: Genome Information System; EHR: Electronic Health Record; PGHD: Person Generated Health Data; 
PACS: Picture Archives and Communication System; CPOE: Computerized Physician Order Entry).
Innate Immunity in Health and Disease
10
200 loci have been identified as an independent contributor to the pathogenesis of 
multiple sclerosis [36]. Multiple sclerosis is usually diagnosed between age 30 and 
50 in most patients and occurs more often in females than male. The best way to 
understand the pathogenesis of multiple sclerosis is to address it from a multifacto-
rial perspective with a model that proposes the interaction among genetic, epigen-
etic, infectious, dietary, climatic, or other environmental effects, together with 
sunlight exposure, and smoking. These interacting factors leads to self-intolerance 
and depreciation of immune homeostasis in the central Nervous system [34]. The 
brain and spinal cord tissues get infiltrated by stimulating peripheral mononuclear 
cells, and this leads to the loss of myelin, gliosis, which often leads to neurological 
dysfunction. Two primary approach of treatment has been given to the patient with 
multiple sclerosis due to the autoimmune model of the pathogenesis of such disease 
[34]. The former treatment is the use of global immunosuppressive agents which are 
aggressive. At the same time, the latter is the use of more specific agents to target 
specific elements of the immune system.
The contribution of common variants to multiple sclerosis has been probed, and 
different HLA alleles variants have been modeled for their contribution to multiple 
sclerosis and were found to be almost as common in control as it is in the sample as 
it was observed that OR of the statistical analysis tends towards 1 with an increase 
in sample size [37]. Biomarkers are important in the genetic assessment of Multiple 
Sclerosis as they possess the ability to express diverse aspects of multiple sclerosis 
heterogeneity. They also help in the diagnosis, stratification, and disease course 
prediction, identification of beneficial therapies and development of a precise 
treatment based on the predicted treatment response. As of 2016, MRI has turned 
to the most appropriate tool in the diagnosis of MS. The recommendation for brain 
MRI is the use of 1.5 T field strength, but 3.0 T is deemed preferable. However, 
using 7 T field strength has been supported by recent evidence to detect central 
vein in brain lesion of MS patients, but this can also be depicted using T2-weighted 
sequences at 3 T which help in the differentiation from microangiopathic lesions. 
The use of MRI for the diagnosis of MS seems simplified but its complexity sets in 
the differentiation of MS from other disease conditions like neuromyelitis optical 
spectrum disorders (NMOSD) which also has short spinal cord lesion at the onset. 
T2-weighted and contrast-enhanced T1-weighted brain MRI are recommended for 
the monitoring of disease progression while MRI of the spinal cord is not encour-
aged. Other than the MRI biomarkers there exist a few body fluid biomarker which 
could mark different stages of MS disease and differentiate each step from other 
similar disease conditions [34].
Body fluid biomarkers can be divided into three main groups, including those 
marking the early phase of MS, those associated with disease course and those 
associated with treatment response. Low vitamin D level in Cerebrospinal fluid is 
a marker of the initial stage of MS. Astrocyte-derived chitinase 3-like 1 (CHI3L1) 
in the CSF is also a prognostic marker of which an increased level of CHI3L1 in 
the CSF is a significant independent risk factor connected with the progression of 
disability in multivariate Cox regression models. Utilizing a proteomic approach 
and verification of result with ELISA confirmed that CHI3L1 would be the best 
predictors of the conversion to MS in CIS patients. CSF CHI3L1 level with MRI and 
age were the best predictors of MS risk in a multivariable analysis. Neurofilaments 
(NF-L) has also been implicated as a biomarker in the early phase of MS [36, 37].
Transcriptional regulator high-mobility group box protein 1 help differenti-
ates patients with relapse-onset MS from patients from primary progressive MS. 
Proteomic studies show that two isoforms of vitamin D-binding protein and 
apolipoprotein E permit discrimination between MS patients with aggressive and 
benign disease courses [36]. During the disease course, calcium-binding protein 
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secretogranin-1 is decreased in the CSF when compared with the early phase 
of MS. Stable MS patients, when compared with relapsing patients, possess an 
increase in B cell activating factors in their plasma samples. Solute carrier family 
9, subfamily A (SLC9A9) is a biomarker associated with the non-response to IFN 
beta. Upregulation of the NLR family, pyrin domain containing 3 (NLRP3) inflam-
masome is also a biomarker for non-responsive IFN beta treatment. Biomarkers of 
glatiramer acetate response are feedback gene to complement 32 (RGC-32), FasL, 
and IL-21. Up-regulated mRNA expression levels of RGC-32 and FasL and reduced 
expression of IL-21 seen in peripheral blood cells from responders in contrast to 
non-responders forms the basis for the use of these biomarkers [34, 36, 37].
2.5.2 Genomic assessment of myasthenia gravis
Myasthenia gravis (MG) is an autoimmune disease treated with chronic immu-
nosuppression due to the actions of autoantibodies against the diverse structure of 
the neuromuscular intersection [38]. The variation of the patient’s response to treat-
ment and the variation in side effects to such treatment is the justifying reason for 
the recognition of the biological markers to predict the effectiveness of each treat-
ment in each patient. Presence of anti-AChR antibodies is a beneficial biomarker in 
the diagnosis of MG. Still, it cannot judge disease severity as no specific correlation 
was found between MG severity and anti-AChR antibodies level [39]. MiR-323b-3p, 
−409-3p, −485-3p, −181d-5p, and − 340-3p has been predicted and suggested as 
response biomarker to project immunosuppressive drug sensitivity in MG patients.
The miRNAs can be tested in the blood, which would make it a potent response 
biomarker for treatment response, and any patient detected not to respond as 
expected will be addressed to other treatments thereby increasing cost-effectiveness. 
MiR-323b-3p, −409-3p and − 485-3p were downregulated in Non-responding 
patients while miRNA-181d-5p, and − 340-3p were upregulated in the Non-
responding patients [39, 40]. A significant association has been identified between 
patient’s response to azathioprine and two haplotypes, the TPMT3E haplotype in the 
thiopurine S-methyltransferase and a haplotype in the ATP-binding cassette sub-fam-
ily C member 6 transporter. The glucocorticoid therapy non-responsive MG patients 
were found to possess a genetic variant in the secreted phosphoprotein 1 (SPP1) gene 
encoding osteopontin, which associates it with the non-responsive group [40].
2.5.3 Genomic assessment of pernicious anemia
Pernicious anemia (PA), is an autoimmune disease which results from a long-
standing infection by Helicobacter pylori and the end-stage of atrophic body gastritis 
(ABG). The condition which is still active gradually phased out by an autoimmunity 
reaction that depletes the gastric mucosa irreversibly. The deficiency of vitamin B12 
has been implicated in the etiology also. Therefore the goal of a clinician in treating 
pernicious anemia may be to avert the signs and symptoms of anemia itself, manage 
its complications such as damage to the nerve and heart tissues, and identifying the 
specific cause where precision medicine comes in [41]. The National Heart, Lung, and 
Blood Institute (NHLBI) are currently carrying out basic and clinical researches that 
could incorporate precision medicine and improve the treatment of the condition.
2.5.4 Genomic assessment of rheumatoid arthritis
Rheumatoid arthritis (RA) is a heterogeneous disease which can range from 
mild, self-limiting arthritis to fast progressive joint damage. It is triggered by a 
complex interaction between the human genetic makeup and the environment. Still, 
Innate Immunity in Health and Disease
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both environmental influence and genetics cannot exhaustively account for the het-
erogenic clinical features of the disease condition. It is also characterized by synovial 
hyperplasia and joint destruction, which can lead to joint deformity or [42].
Currently, the treatment of RA is based on the control of inflammation with 
which an effective therapy that comes early ensures a drastic reduction in the risk 
of joint damage, mortality and disability. As of 2017, major researches has focused 
on the identification of biomarkers that can predict patient’s response to only 
Methotrexate (MTX) which is the first non-biologic therapeutic agent adminis-
tered. Also, TNF inhibitors (TNFi) has been established to be ineffective in about 
30% of patients but remains the first choice of available biologic therapeutic agents. 
Solute carrier family 19 member 1 (SLC19A1) gene possess the most consistent and 
relevant evidence. It is one of the many transport carriers that allow the transport of 
MTX into the cell [43].
Anti- CCP antibodies a genomic marker associated with poor prognosis as it 
relates to the severity of disease and the extent of damage caused on the joint, HLA-
DRB1 alleles coding for shared epitope is another marker for severity in RA [44].
2.5.5 Genomic assessment of sjogren syndrome
Sjögren’s syndrome (SS) is a form of B cell hypersensitivity which is manifested 
in the formation of excess autoantibodies and a strong propensity for NHL of B cell 
emergence [45]. About 5% of patients of primary SS are at risk of lymphoma devel-
opment. However, it is vital to have a specific biomarker to identify such patient 
early to be able to monitor and detect early and select appropriate therapy. The 
diagnostic biomarkers will guide in the diagnosis, and the predictive biomarkers 
are meant to show another aspect of clinical decision. Cytopenias is an established 
prognostic biomarker for the development of lymphoma [46]. A lot of proposed 
biomarkers in the assessment of SS are yet to be confirmed in more extensive stud-
ies before adoption into clinical use [47].
2.5.6 Genomic assessment of systemic lupus erythematosus
The systemic lupus erythematosus (SLE) has a broad spectrum of signs and 
symptoms which varies among patients and involves numerous organs with skin, 
joints, kidneys, lungs and CNS included. It is a chronic inflammatory autoimmune 
disease [48]. An association has been established between SLE and human leuko-
cyte antigen (HLA) haplotypes (HLA-DR3; DR9; DR15; DQA1*0101 especially). 
The extensive association has also been found between vitamin D matching up with 
serum concentrations and vitamin D-receptor genomic binding domains [49].
2.5.7 Genomic assessment of type 1 diabetes
The type 1 diabetes (T1D) takes place as a result of autoimmune beta-cell 
destruction, which leads to insufficient production of insulin and results in hyper-
glycemia [50]. Although the role of precision medicine in type 1 diabetes is not well 
defined, patient with T1D severity varies with difference in their pancreatic autoan-
tibodies profile and the rate at which their beta cells destroy [51].
In genetic studies (an important feature of precision medicine), identification 
of over 50 genetic signals in notably HLA region has been found to influence T1D 
predisposition [52]. The diagnostic biomarkers (serum biomarkers) use in the diag-
nosis of T1D includes the combination of glucose, C-peptide, glycated molecules 
and autoantibodies established for T1D. Still, these molecules often mark the late 
stage of the disease [53].
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So far, advance in genomic research introduces the administration of islet 
autoantigens or peptides into a recipient with the risk of T1D; these studies suggest 
promising changes in immune regulation of islet autoimmunity. The challenges 
remain dosing frequency, dosage, route of administration, and adjuvants use.
2.6 Future perspectives
i. A systemic follow up of variant genes like the TNFRSF1A that is connected 
with multiple sclerosis risk should be closely investigated by researchers. 
This gene could give an essential perception of the etiology of multiple 
sclerosis and new treatment strategies.
ii. Myasthenia gravis-related loci may display their involvement in the patho-
genesis of immune disease by increasing immune response, repression of the 
mechanism involved in immune suppression, alteration of procedure that 
differentiates between autologous and heterologous molecular configuration 
through immune tolerance, therefore investigations into Single nucleotide 
polymorphisms (SNPs) in the general population that is associated with 
Myasthenia gravis will improve diagnosis, therapy and its outcome.
iii. Genome editing technologies have been used with a degree of success in the 
treatment of sickle cell disease and β-thalassemia, this could be introduced 
into the precise treatment of pernicious anemia with proper study of the 
gene encoding for mitochondrial transport of vitamin B12.
iv. Rheumatoid arthritis research should focus on discovering more associated 
genes and their resultant effects. Transcriptomic and epigenomic strategies 
should also be used in discovering biomarkers of response to treatments and 
pathways that are related to therapies. Integration of genetic, clinical and 
environmental data are also crucial in achieving the aim of precision medi-
cine in the treatment of rheumatoid arthritis.
v. Selection of novel treatments could be achieved for sjogren syndrome by 
identification of genetic risk factors like that of profound interferon signal-
ing pathway by IRF5 and STAT 4 genes.
vi. Prevention of systemic lupus erythematosus by assaying genetic profile, 
developing new biomarkers of immune activation and alteration is the 
precise future treatment of this condition.
vii. Investigations into genes and pathways of type 1 diabetes may reveal on 
time the pathogenic role of the destruction of β-cell and production of 
clinical disease by the innate and adaptive immune system. Type 1 Diabetes 
Genetics Consortium (T1DGC) international have resources that could help 
in diagnosis, interventions, and monitoring outcomes of treatment of type 1 
diabetes.
As the era of ‘Big Health Data’ continues, it is essential for the diagnosis, prog-
nosis and treatment monitoring efforts on autoimmune diseases to take advantage 
of the data and different machine learning and deep learning algorithms to establish 
patterns and clusters within the disease groups. This will help in the identifica-
tion of more relevant biomarkers and also help in the easy transition of biomarker 
researches to the bedside.
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Indeed, the application of precision medicine in autoimmune diseases depends 
on the progress of next-generation sequencing program, which at the same time 
will strive to provide not only a whole-exome, or transcriptome, but at an exact 
process that is cost-efficient.
3. Conclusions
The information provided by the Genomics data is an indispensable component 
of precision medicine as it holds the key to the explanation in individual variability 
and evolution [54]. But, the clinical use of genomic data still needs to be improved 
on to overcome challenges stated by Kim et al. [55] like:
a. The incongruity between the form of genomic and clinical information: as a 
result of extensive (several tens of gigabytes of sequence) data in the genomic 
data, clinical data cannot be processed in the clinical practice without addi-
tional processing [55, 56].
b. The difference in the properties of genomic data and observational data used in 
the clinical settings: given that the genomic workflows hold a large number of 
data, data obtained from this workflows is undoubtedly different from systems 
parallel to the clinical plan [57].
c. Difficulty in mapping the genomic and clinical data for medical interpreta-
tion: as seen in the case of targeted sequencing, where most data are processed 
before medical analysis [58].
Also, there is no international validation for biomarkers in use; there is a need 
for international collaboration to validate biomarkers presently in existence.
Overcoming these challenges will open up more opportunities for the use of 
genomic data in clinical practices.
Conflict of interest
The authors declare no conflict of interest.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
15
Precision Medicine of Autoimmune Diseases
DOI: http://dx.doi.org/10.5772/intechopen.95248
[1] Musa M. Immune mechanism: A 
“double-edged sword.” Malaysian J Med 
Sci. 2013;20(3):61-67.
[2] Corra L. CHILDREN AND 
NOISE - Children ’ s Health and the 
Environment. World Heal Organ. 
Published online 2009:1-67.
[3] Akira S, Uematsu S, Takeuchi O.  
Pathogen recognition and innate 
immunity. Cell. 2006;124(4):783-801. 
doi:10.1016/j.cell.2006.02.015
[4] Shurin MR, Smolkin YS. Immune-
mediated diseases II congress: Summary. 
J Immunotoxicol. 2008;5(2):159-162. 
doi:10.1080/15476910802129604
[5] Tangye SG, Al-Herz W, 
Bousfiha A, et al. Human Inborn Errors 
of Immunity: 2019 Update on the 
Classification from the International 
Union of Immunological Societies 
Expert Committee. J Clin Immunol. 
2020;40(1):24-64. doi:10.1007/
s10875-019-00737-x
[6] Chinen J, Shearer WT. Secondary 
immunodeficiencies, including HIV 
infection. J Allergy Clin Immunol. 
2010;125(2 SUPPL. 2):S195-S203. 
doi:10.1016/j.jaci.2009.08.040
[7] Delhalle S, Bode SFN, Balling R, 
Ollert M, He FQ. A roadmap towards 
personalized immunology. npj Syst 
Biol Appl. 2018;4(1). doi:10.1038/
s41540-017-0045-9
[8] Gafson A, Craner MJ, 
Matthews PM. Personalised medicine 
for multiple sclerosis care. 
Mult Scler. 2017;23(3):362-369. 
doi:10.1177/1352458516672017
[9] Janeway CA, Medzhitov R. 




[10] Tangye SG, Al-Herz W, Bousfiha A, 
et al. Molecules, Cells, and Tissues 
of Immunity. Annu Rev Immunol. 
2004;20(3):1-67. doi:10.1016/j.
cell.2006.02.015
[11] Akira S, Takeda K, Kaisho T. 
Toll-like receptors : critical proteins. 
2001;2(8).
[12] Doolan DL, Dobaño C, Baird JK. 
Acquired immunity to Malaria. Clin 
Microbiol Rev. 2009;22(1):13-36. 
doi:10.1128/CMR.00025-08
[13] Elias K, Siegel R, 
O’Shea JJ. Molecular and cellular basis 
of immunity and immunological 
diseases. Prim Rheum Dis Thirteen 
Ed. Published online 2008:94-107. 
doi:10.1007/978-0-387-68566-3_4
[14] Galli SJ. Toward precision medicine 
and health: Opportunities and 
challenges in allergic diseases. J Allergy 
Clin Immunol. 2016;137(5):1289-1300. 
doi:10.1016/j.jaci.2016.03.006
[15] Jackson, Sarah E, and John D 
Chester. “Personalised cancer medicine.” 
International journal of cancer vol. 137,2 
(2015): 262-6. doi:10.1002/ijc.28940
[16] Cirillo D, Valencia A. Big data 
analytics for personalized medicine. 
Curr Opin Biotechnol. 2019 Aug;58:161-
167. doi: 10.1016/j.copbio.2019.03.004. 
Epub 2019 Apr 6. PMID: 30965188.
[17] Dinov ID. Volume and Value 
of Big Healthcare Data. J Med Stat 
Inform. 2016;4:3. doi: 10.7243/2053-
7662-4-3. PMID: 26998309; PMCID: 
PMC4795481.
[18] Hulsen T, Jamuar SS, Moody AR, 
Karnes JH, Varga O, Hedensted S, 
Spreafico R, Hafler DA, McKinney EF. 
From Big Data to Precision Medicine. 
Front Med (Lausanne). 2019 Mar 1;6:34. 
doi: 10.3389/fmed.2019.00034.
References
Innate Immunity in Health and Disease
16
[19] Timothée Proix, Fabrice 
Bartolomei, Maxime Guye, Viktor K. 
Jirsa, Individual brain structure and 
modelling predict seizure propagation, 
Brain, Volume 140, Issue 3, March 2017, 
Pages 641-654, doi: 10.1093/brain/
awx004.
[20] José María Fernández, Victor de la 
Torre, David Richardson, Romina Royo, 
Montserrat Puiggròs, Valentí Moncunill, 
Stamatina Fragkogianni, Laura Clarke, 
Paul Flicek, Daniel Rico, David 
Torrents, Enrique Carrillo de Santa Pau, 
Alfonso Valencia. The BLUEPRINT 
Data Analysis Portal, Cell Systems, 
2016, ISSN 2405-4712, doi:10.1016/j.
cels.2016.10.021.
[21] Yan Q. Immunoinformatics 
and Systems Biology Methods for 
Personalized Medicine. In: Yan Q. (eds) 
Systems Biology in Drug Discovery and 
Development. Methods in Molecular 
Biology (Methods and Protocols), 2010, 
vol 662. Humana Press, Totowa, NJ. 
doi:10.1007/978-1-60761-800-3_10
[22] Yalan Chen, Xingyun Liu, Yijun Yu, 
Chunjiang Yu, Lan Yang, Yuxin Lin, 
Ting Xi, Ziyun Ye, Zhe Feng, Bairong 
Shen, PCaLiStDB: a lifestyle database 
for precision prevention of prostate 
cancer, Database, Volume 2020, 2020, 
baz154, doi:10.1093/database/baz154
[23] Rehm HL, Berg JS, Brooks LD, 
Bustamante CD, Evans JP, Landrum MJ, 
Ledbetter DH, Maglott DR, Martin CL, 
Nussbaum RL, Plon SE. ClinGen—
the clinical genome resource. New 
England Journal of Medicine. 2015 
Jun 4;372(23):2235-42. DOI: 10.1056/
NEJMsr1406261
[24] Miriam S. Reuter, Susan Walker, 
Bhooma Thiruvahindrapuram, Joe 
Whitney, Iris Cohn, Neal Sondheimer, 
Ryan K.C. Yuen, Bret.t Trost, 
Tara A. Paton, Sergio L. Pereira, 
Jo-Anne Herbrick, Richard F. Wintle, 
Daniele Merico, Jennifer Howe, 
Jeffrey R. MacDonald, Chao Lu, 
Thomas Nalpathamkalam, Wilson W.L. 
Sung, Zhuozhi Wang, Rohan V. Patel, 
Giovanna Pellecchia, John Wei, Lisa J. 
Strug, Sherilyn Bell, Barbara Kellam, 
Melanie M. Mahtani, Anne S. Bassett, 
Yvonne Bombard, Rosanna Weksberg, 
Cheryl Shuman, Ronald D. Cohn, 
Dimitri J. Stavropoulos, Sarah Bowdin, 
Matthew R. Hildebrandt, Wei Wei, 
Asli Romm, Peter Pasceri, James 
Ellis, Peter Ray, M. Stephen Meyn, 
Nasim Monfared, S. Mohsen Hosseini, 
Ann M. Joseph-George, Fred W. Keeley, 
Ryan A. Cook, Marc Fiume, Hin C. 
Lee, Christian R. Marshall, Jill Davies, 
Allison Hazell, Janet A. Buchanan, 
Michael J. Szego, Stephen W. Scherer. 
The Personal Genome Project Canada: 
findings from whole genome sequences 
of the inaugural 56 participants. CMAJ 
2018, 190 (5) E126-E136; doi: 10.1503/
cmaj.171151
[25] Madeleine P. Ball, Joseph V. 
Thakuria, Alexander Wait Zaranek, 
TomClegg, AbrahamM. Rosenbaum, 
Xiaodi Wu, Misha Angrist, Jong Bhak, 
Jason Bobe, MatthewJ. Callow, Carlos 
Cano, MichaelF. Chou, Wendy K.Chung, 
Shawn M. Douglas, Preston W. Estep, 
Athurva Gore, Peter Hulick, Alberto 
Labarga, Je-Hyuk Lee, Jeantine E. 
Lunshof, Byung Chul Kim, Jong-Il Kim, 
Zhe Li, Michael F. Murray, Geoffrey B. 
Nilsen, Brock A. Peters, Anugraha M. 
Raman, Hugh Y. Rienhoff, Kimberly 
Robasky, Matthew T.Wheeler, Ward 
Vandewege, Daniel B. Vorhaus, Joyce L. 
Yang, LuhanYang, John Aach, Euan A. 
Ashley, Radoje Drmanac, Seong-Jin Kim, 
Jin Billy Li, Leonid Peshkin, Christine E. 
Seidman, Jeong-Sun Seo, Kun Zhang, 
Heidi L. Rehm, George M. Church. 
A public resource for clinical use of 
genomesSciences. 2012, 109 (30) 11920-
11927; doi:10.1073/pnas.1201904109
[26] (OMIM) Online Mendelian 
Inheritance in Man An Online Catalog 
of Human Genes and Genetic Disorders 
Updated October 14, 2020. (Retrieved 
from https://omim.org/ on 15th of 
October 2020)
17
Precision Medicine of Autoimmune Diseases
DOI: http://dx.doi.org/10.5772/intechopen.95248
[27] Benjamin D. Solomon, Anh-
Dao Nguyen, Kelly A. Bear, and 
Tyra G. Wolfsberg PNAS June 11, 
2013;110(24):9851-9855; doi:10.1073/
pnas.1302575110
[28] (HGMD) The Human Gene 
Mutation Database, at the Institute of 
Medical Genetics in Cardiff retrieved 
on 15/10/2020 from http://www.hgmd.
cf.ac.uk/ac/index.php
[29] (HVP) Human Variome Project 
retrieved on 15/10/2020 from https://
www.humanvariomeproject.org/
[30] Stimson, Nancy F. “Personalized 
medicine: selected web resources.” 
Dialogues in clinical neuroscience vol. 
2009;11(4):464-9.
[31] Alessandro Blasimme, Marta Fadda, 
Manuel Schneider, and Effy Vayena. 
Data Sharing For Precision Medicine: 
Policy Lessons And Future Directions, 
Health Affairs, 2018;37(5):702-709,
[32] Marrack P, Kappler J, Kotzin BL. 
Autoimmune disease: why and where 
it occurs. Nat Med. 2001;7(8):899-905. 
doi: 10.1038/90935.
[33] Ngo, S. T., Steyn, F. J., & 
McCombe, P. A. Gender differences 
in autoimmune disease. Frontiers in 
Neuroendocrinology, 2014;35(3):347-
369. doi:10.1016/j.yfrne.2014.04.004
[34] Bose G, Freedman MS. 
Precision medicine in the multiple 
sclerosis clinic: Selecting the right 
patient for the right treatment. 
Mult Scler J. 2020;26(5):540-547. 
doi:10.1177/1352458519887324
[35] Baranzini SE, Oksenberg JR. The 
Genetics of Multiple Sclerosis: From 
0 to 200 in 50 Years. Trends Genet. 
2017;33(12):960-970. doi:10.1016/j.
tig.2017.09.004
[36] Chitnis T, Prat A. A roadmap 
to precision medicine for multiple 
sclerosis. Mult Scler J. 2020;26(5):522-
532. doi:10.1177/1352458519881558
[37] Comabella M, Sastre-Garriga J, 
Montalban X. Precision medicine in 
multiple sclerosis: Biomarkers for 
diagnosis, prognosis, and treatment 
response. Curr Opin Neurol. 
2016;29(3):254-262. doi:10.1097/
WCO.0000000000000336
[38] Meriggioli MN, Sanders DB. 
Autoimmune myasthenia gravis: 
emerging clinical and biological 
heterogeneity. Lancet Neurol. 
2009;8(5):475-490. doi:10.1016/
S1474-4422(09)70063-8
[39] Cavalcante P, Mizrachi T, 
Barzago C, et al. MicroRNA signature 
associated with treatment response 
in myasthenia gravis: A further step 
towards precision medicine. Pharmacol 
Res. 2019;148(June). doi:10.1016/j.
phrs.2019.104388
[40] Mantegazza R, Cavalcante P. 
Diagnosis and treatment of myasthenia 
gravis. Curr Opin Rheumatol. 
2019;31(6):623-633. doi:10.1097/
BOR.0000000000000647
[41] Annibale B, Lahner E, Fave GD.  
Diagnosis and management of 
pernicious anemia. Curr Gastroenterol 
Rep. 2011;13(6):518-524. doi:10.1007/
s11894-011-0225-5
[42] Guo S, Xu L, Chang C, Zhang R, 
Jin Y, He D. Epigenetic Regulation 
Mediated by Methylation in the 
Pathogenesis and Precision Medicine 
of Rheumatoid Arthritis. Front Genet. 
2020;11(August):1-9. doi:10.3389/
fgene.2020.00811
[43] Bluett J, Barton A. Precision Medicine 
in Rheumatoid Arthritis. Rheum Dis 
Clin North Am. 2017;43(3):377-387. 
doi:10.1016/j.rdc.2017.04.008
[44] Kaneko Y, Takeuchi T. Targeted 
antibody therapy and relevant novel 
biomarkers for precision medicine for 
Innate Immunity in Health and Disease
18
rheumatoid arthritis. Int Immunol. 
2017;29(11):511-517. doi:10.1093/
intimm/dxx055
[45] Goules A V., Tzioufas AG.  
Lymphomagenesis in Sjögren’s 
syndrome: Predictive biomarkers 
towards precision medicine. 
Autoimmun Rev. 2019;18(2):137-143. 
doi:10.1016/j.autrev.2018.08.007
[46] Retamozo S, Brito-Zerón P, 
Ramos-Casals M. Prognostic markers 
of lymphoma development in 
primary Sjögren syndrome. 
Lupus. 2019;28(8):923-936. 
doi:10.1177/0961203319857132
[47] Baldini C, Ferro F, Elefante E, 
Bombardieri S. Biomarkers for Sj ogren ’ 
s syndrome. Published online 2018.
[48] Chen L, Wang YF, Liu L,  
Bielowka A, Ahmed R, Zhang H, 
Tombleson P, Roberts AL, Odhams CA, 
Cunninghame Graham DS, Zhang X, 
Yang W, Vyse TJ, Morris DL. Genome-
wide assessment of genetic risk for 
systemic lupus erythematosus and 
disease severity. Hum Mol Genet. 2020 
Jun 27;29(10):1745-1756. doi: 10.1093/
hmg/ddaa030. PMID: 32077931; 
PMCID: PMC7322569.
[49] Lever E, Alves MR, Isenberg DA. 
Towards precision medicine in systemic 
lupus erythematosus. Pharmgenomics 
Pers Med. 2020;13:39-49. doi:10.2147/
PGPM.S205079
[50] Kalra, S., Das, A.K., Bajaj, S. et 
al. Utility of Precision Medicine in 
the Management of Diabetes: Expert 
Opinion from an International Panel. 
Diabetes Ther 2020;11:411-422 . 
doi:10.1007/s13300-019-00753-5
[51] Mohan V, Unnikrishnan R. Precision 
diabetes: Where do we stand today?. 
Indian J Med Res. 2018;148(5):472-475. 
doi:10.4103/ijmr.IJMR_1628_18
[52] Miriam S Udler, Mark I McCarthy, 
Jose C Florez, Anubha Mahajan, Genetic 
Risk Scores for Diabetes Diagnosis 
and Precision Medicine, Endocrine 
Reviews, 40 (6) 2019, Pages 1500-1520, 
doi:10.1210/er.2019-00088
[53] Yi L, Swensen AC, Qian WJ. 
Serum biomarkers for diagnosis and 
prediction of type 1 diabetes. Transl 
Res. 2018 Nov;201:13-25. doi: 10.1016/j.
trsl.2018.07.009.
[54] Collins, F. S. & Varmus, H. A 
new initiative on precision medicine. 
New England Journal of Medicine 
372, 793-795 (2015). DOI: 10.1056/
NEJMp1500523
[55] Kim, H.J., Kim, H.J., Park, Y. et al. 
Clinical Genome Data Model (cGDM) 
provides Interactive Clinical Decision 
Support for Precision Medicine. 
Sci Rep 2020;10:1414. doi:10.1038/
s41598-020-58088-2
[56] Lubin Ira M., Nazneen Aziz, 
Lawrence J. Babb, Dennis Ballinger, 
Himani Bisht, Deanna M. Church, 
Shaun Cordes, Karen Eilbeck, 
Fiona Hyland, Lisa Kalman, Melissa 
Landrum, Edward R. Lockhart, 
Donna Maglott, Gabor Marth, John D. 
Pfeifer, Heidi L. Rehm, Somak Roy, 
Zivana Tezak, Rebecca Truty, Mollie 
Ullman-Cullere, Karl V. Voelkerding, 
Elizabeth A. Worthey, Alexander W. 
Zaranek, Justin M. Zook. Principles and 
Recommendations for Standardizing the 
Use of the Next-Generation Sequencing 
Variant File in Clinical Settings. 
2017, ISSN 1525-1578, doi:10.1016/j.
jmoldx.2016.12.001.
[57] Kho, A., Rasmussen, L., Connolly, J. 
et al. Practical challenges in integrating 
genomic data into the electronic health 
record. Genet Med 2013;15, 772-778. 
doi:10.1038/gim.2013.131
[58] Roukos, D. H. Next-generation, 
genome sequencing-based biomarkers: 
concerns and challenges for medical 
practice. Biomarkers in medicine 
2010;4:583-586. doi:10.2217/bmm.10.70.
